Vimarsana
Biggest News Aggregation in the World

Page 33 - Inducement Plan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Inducement Plan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Inducement Plan Today - Breaking & Trending Today

Aquestive Therapeutics Strengthens Team to Align with - Vimarsana News

Aquestive Therapeutics Strengthens Team to Align with

Appoints Timothy E. Morris, a veteran biotech executive with over 35 years of experience in executive and financial leadership, to Board of DirectorsNames...

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Vimarsana News

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to...

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Vimarsana News

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to...

Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Vimarsana News

Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EMERYVILLE, Calif.--(BUSINESS WIRE)--#earnings--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that effective August 1, 2022, Ligand’s Board of Directors approved the grant of non-qualified stock option awards to purchase an aggregate of 90,073 shares of its common stock, 5,000 restricted stock u...

Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Press Release - Vimarsana News

Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Press Release

Ligand Pharmaceuticals Incorporated LGND today announced that effective August 1, 2022, Ligand's Board of Directors approved the grant of non-qualifie